Skip to content
drillr.ai
Sign up

09989.HK

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

Also listed · 002399.SZ →
HKD 3.94
+1.42%
Ask drillr

  • Oct 29, 2026, 08:47 UTC

    Hepalink reported net profit attributable to shareholders of RMB394 million for the nine months ended September 30, 2026, down 28.84% year over year, and third-quarter net profit of RMB119 million, down 9.95%, with earnings per share of RMB0.2685 and RMB0.0808, respectively.

    Source:

  • Aug 28, 2026, 08:42 UTC

    Hepalink announced its H1 2026 results: revenue of 2.58 billion yuan, down 8.44% year-on-year; net profit attributable to shareholders of 275 million yuan, down 34.74% year-on-year; non-GAAP net profit of 162 million yuan, down 62.01% year-on-year. The company plans no cash dividend, no bonus shares, and no capital reserve conversion.

    Source: